Kamal Adawi - 15 Jan 2026 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Reporting relationship: Chief Financial Officer
Issuer ticker: FATE
Reported as of: 15 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jan 2026, 16:02:16 UTC
Prior SEC filing: 21 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Cindy Tahl, as Attorney-in-Fact

Key filing fact

Kamal Adawi filed Form 4 for FATE THERAPEUTICS INC (FATE) on 16 Jan 2026.

Key facts

This page summarizes Kamal Adawi's Form 4 filing for FATE THERAPEUTICS INC (FATE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jan 2026, 16:02.

Change

Previous filing in this sequence was filed on 21 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001788393 Primary reporting owner

Adawi Kamal

Relationship: Chief Financial Officer
Address: C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO
Signature: /s/ Cindy Tahl, as Attorney-in-Fact
Signature date: 16 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FATE transaction

Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %: +33%
Price: $0.000000
Shares after: 100,000
Date: 15 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FATE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 15 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $1.05
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award of restricted stock units ("RSUs") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.

Footnote F2

The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.